February 3, 2015
Brickell Announces $10M Series C Financing.
Initiates Phase 2b Study of BBI-4000 in Patients with Axillary Hyperhidrosis.
Acquires Novel, Clinical-Stage Compound for the Oral Treatment of Atopic Dermatitis.
Focused on the development of novel therapies for the treatment of skin diseases.
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative, first-in-class therapeutics to satisfy current unmet human needs in the global dermatology markets.
Brickell Biotech, Inc. © 2015 All Rights Reserved.